Last updated: 2026-09-06 16:55:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Capricor Therapeutics Inc. (CAPR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $9,42, with a market capitalization of $574,99M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,96 to $40,37. This page covers its latest market performance, valuation, price trends and company information.
$574,99M | |
$9,40 | |
$106,80 | |
$0,88 | |
$9,28 | |
2,34M | |
-- | |
-- | |
$40,37 | |
$2,96 | |
-- | |
-- |
Capricor Therapeutics Inc. (CAPR) last closed at $9,28 as of 2026-09-04 23:54:00, unchanged from the previous close of $9,28.
During the latest regular trading session, CAPR traded between $0,88 and $106,80, with a volume of 2,34M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Capricor Therapeutics Inc. (CAPR) moved from $9,50 to $9,42, representing a decline of 0,79% ($0,07).
The stock traded between $9,20 and $9,80 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 5,70 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 17,3%
CAPR is currently trading at $9,42, placing it 17,3% of the way from its 52-week low of $2,96 to its 52-week high of $40,37. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 231 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Capricor Therapeutics Inc. (CAPR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.